These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9465846)

  • 1. [Protease inhibitors are effective not only in AIDS].
    Wehr A
    Dtsch Med Wochenschr; 1998 Jan; 123(1-2):A9-10. PubMed ID: 9465846
    [No Abstract]   [Full Text] [Related]  

  • 2. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
    Wang D; Li W; Pechar M; Kopecková P; Brömme D; Kopecek J
    Int J Pharm; 2004 Jun; 277(1-2):73-9. PubMed ID: 15158970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental models to identify antimetastatic drugs: are we there yet? A position paper.
    Zucker S
    Ann N Y Acad Sci; 1999 Jun; 878():208-11. PubMed ID: 10415732
    [No Abstract]   [Full Text] [Related]  

  • 4. 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents.
    Deaton DN; Kumar S
    Prog Med Chem; 2004; 42():245-375. PubMed ID: 15003723
    [No Abstract]   [Full Text] [Related]  

  • 5. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.
    Black WC; Bayly CI; Davis DE; Desmarais S; Falgueyret JP; Léger S; Li CS; Massé F; McKay DJ; Palmer JT; Percival MD; Robichaud J; Tsou N; Zamboni R
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4741-4. PubMed ID: 16154747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease inhibitors: a panacea?
    Haq SK; Rabbani G; Ahmad E; Atif SM; Khan RH
    J Biochem Mol Toxicol; 2010; 24(4):270-7. PubMed ID: 20135636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of proteases as anticancer drugs.
    Jedinak A; Maliar T
    Neoplasma; 2005; 52(3):185-92. PubMed ID: 15875078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
    Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
    Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
    Palmer JT; Hirschbein BL; Cheung H; McCarter J; Janc JW; Yu ZW; Wesolowski G
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2909-14. PubMed ID: 16546382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in cathepsin K inhibitor design.
    Grabowskal U; Chambers TJ; Shiroo M
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):619-30. PubMed ID: 16159024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural biflavones as novel inhibitors of cathepsin B and K.
    Zeng GZ; Pan XL; Tan NH; Xiong J; Zhang YM
    Eur J Med Chem; 2006 Nov; 41(11):1247-52. PubMed ID: 16828525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
    Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Ray JA; Samano V; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1735-9. PubMed ID: 16376075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors.
    Banke IJ; Arlt MJ; Pennington C; Kopitz C; Steinmetzer T; Schweinitz A; Gansbacher B; Quigley JP; Edwards DR; Stürzebecher J; Krüger A
    Biol Chem; 2003; 384(10-11):1515-25. PubMed ID: 14669995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.
    Morley AD; Kenny PW; Burton B; Heald RA; Macfaul PA; Mullett J; Page K; Porres SS; Ribeiro LR; Smith P; Ward S; Wilkinson TJ
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1658-61. PubMed ID: 19231183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
    Stoch SA; Wagner JA
    Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
    Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
    J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
    Tavares FX; Deaton DN; Miller AB; Miller LR; Wright LL; Zhou HQ
    J Med Chem; 2004 Oct; 47(21):5049-56. PubMed ID: 15456248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G.
    Maryanoff BE
    J Med Chem; 2004 Feb; 47(4):769-87. PubMed ID: 14761180
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis.
    Robichaud J; Black WC; Thérien M; Paquet J; Oballa RM; Bayly CI; McKay DJ; Wang Q; Isabel E; Léger S; Mellon C; Kimmel DB; Wesolowski G; Percival MD; Massé F; Desmarais S; Falgueyret JP; Crane SN
    J Med Chem; 2008 Oct; 51(20):6410-20. PubMed ID: 18811135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.